A Study to Evaluate Social Functioning of Long Acting Injectable Risperidone and Oral Risperidone in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of the study is to evaluate the effect long-acting injectable risperidone and oral risperidone treatment has on the social functioning of patients with schizophrenia or schizoaffective disorder.
| Condition | Intervention | Phase |
|---|---|---|
|
Schizophrenia Psychotic Disorders |
Drug: Long-acting injectable risperidone and oral risperidone |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Randomized, Open-label, Active-controlled Study to Evaluate Social Functioning of Long Acting Injectable Risperidone and Oral Risperidone in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder |
- The primary outcome measure is PSP scale to evaluate the improvement in social functions among patients taking long-acting injectable risperidone compared with oral risperidone after treatment respectively for 12 months. [ Time Frame: The primary outcome measure is assessed at baseline, 6-month and 12-month or early withdrawal. ] [ Designated as safety issue: No ]
- To evaluate the efficacy and safety by comparing the scores of the following assessment tools: PANSS, CGI-S, AIMS, SAS, BARS and AE reports [ Time Frame: baseline, 1-month, 2-month, 3-month, 4-month, 5-month, 6-month, 9-month and 12-month or early withdrawal ] [ Designated as safety issue: No ]
- To obtain pharmaco economic data using the health economic questionnaire [ Time Frame: baseline, 6-month, 12-month or early withdrawal ] [ Designated as safety issue: No ]
- To evaluate the cognitive functions and improvements in overall quality of life by comparing the scores of the following assessment tools: neurocognitive function battery, GAF, SUMD, SFS, PWI, DAI and emotional social function scale [ Time Frame: baseline, 6-month, 12-month or early withdrawal ] [ Designated as safety issue: No ]
| Enrollment: | 50 |
| Study Start Date: | August 2007 |
| Study Completion Date: | December 2010 |
| Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
This is a randomized (treatment group assigned by chance), open-label (all involved people know the identity of the study drug), active-controlled study to evaluate the social functioning of long-acting injectable risperidone and oral risperidone in the treatment of patients with schizophrenia or schizoaffective disorders. The primary objective of this study is to evaluate the improvement in social functions among patients taking long-acting injectable risperidone, compared with oral risperidone, after treatment respectively for 12 months. The secondary objectives of this study are to evaluate the efficacy and safety of the compound and to evaluate drop out rates, cognitive function, improvement in overall quality of life and health economic data after treatment with long-acting injectable risperidone and oral risperidone. The study drug will be administered for 52 weeks as flexible dosage (dose range is according to the local label and adjusted by clinician discretion) and a total of 11 assessment occasions will be conducted, including the screening phase, per patient. The patient may be withdrawn from the trial for any medical reason at the sole discretion of the investigator. Antipsychotic drugs administered to the patients will be limited to long-acting injectable risperidone and oral risperidone. The supplement of oral risperidone for the first 3 - 4 weeks during the administration of long-acting injectable risperidone is also required. The aim is to examine changes in social and occupational functioning after 12 months of treatment among each group, using the PSP (personal and social performance scale) for measurement. Primary efficacy measure is PSP and secondary efficacy measures are PANSS (positive and negative syndrome scale), CGI-S (clinical global impression-severity), SFS (social functioning scale), Emotional & Social Functioning Scale, Neurocognitive Function Test; CPT(continuous performance task), COWAT(controlled word association task), K-WAIS (Korean-Wechsler adult intelligence scale) and TOM(theory of mind) , HE (health-economic) Questionnaire, PWI (psychosocial well-being index), DAI (drug attitude inventory), SUMD (scale to assess unawareness of mental disorder), GAF (global assessment of functioning). Safety evaluations are AIMS (abnormal involuntary movement scale), BARS (barnes akathisia rating scale), SAS (simpson-angus rating scale) and adverse events/serious adverse events reporting. The study includes run-in period during minimum 2 weeks for stabilizing to risperidone. In this period patients take oral risperidone. Patients who randomized each treatment group in baseline will visit every 2 weeks and take long-acting injectable risperidone or oral risperidone for treatment period of 52 weeks.
Eligibility| Ages Eligible for Study: | 18 Years to 55 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Schizophrenic or schizoaffective patient (hospitalized or outpatient) who require long-term antipsychotic drug therapy
- A signed informed consent document, indicating that the patient understands the purposes of, and procedures relating to, the study, and are willing to participate in it
- Patients whose informed consent forms were signed by either the patient, their caregivers, or legal representative
- Patient with more than 71 points in a premorbid GAF score, (as determined as a result of their medical history), as evaluated at the time of screening
- Patient who did not exhibit clinically significant abnormalities in the biochemical test and the electrocardiogram (ECG)
- Patient who intends to be compliant with, will be available and willing to fulfill the requirements of the trial
Exclusion Criteria:
- Patient administered clozapine within the 3 months previous to the commencement of the trial
- Patient with mental retardation (with an IQ less than 70 at screening)
- Patient with a history of serious alcohol or drug addiction over the 6 months previous to the commencement of the trial
- Patient with serious diseases, (cardiovascular, respiratory, neurological - including the suffering of seizures or significant cerebrovascular disease), renal, hepatic, hematologic, endocrine, immunological, or other systemic diseases), which include abnormal values recently and/or currently clinically relevant
- Patient with a history of Neuroleptic Malignancy Syndrome and Tardive Dyskinesia
- Patient hyper-responsive or allergic to risperidone, or who are completely unresponsive to risperidone
- Female patient who is pregnant or breast-feeding
Contacts and Locations More Information
No publications provided
| Responsible Party: | Medical Director, Janssen Korea, Ltd., Korea |
| ClinicalTrials.gov Identifier: | NCT00992407 History of Changes |
| Other Study ID Numbers: | CR015841 |
| Study First Received: | October 8, 2009 |
| Last Updated: | December 9, 2011 |
| Health Authority: | Korea: Food and Drug Administration |
Keywords provided by Janssen Korea, Ltd., Korea:
|
Long acting injectable risperidone Oral risperidone Schizophrenia Schizoaffective disorder |
Randomization Social function Health economic |
Additional relevant MeSH terms:
|
Psychotic Disorders Mental Disorders Schizophrenia Schizophrenia and Disorders with Psychotic Features Risperidone Serotonin Antagonists Serotonin Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Pharmacologic Actions |
Physiological Effects of Drugs Antipsychotic Agents Tranquilizing Agents Central Nervous System Depressants Central Nervous System Agents Therapeutic Uses Psychotropic Drugs Dopamine Antagonists Dopamine Agents |
ClinicalTrials.gov processed this record on June 17, 2013